The results of a comparative analysis of the population of the population of Ukraine and countries of the European region for HIV as a rationale for improving the pharmaceutical provision of patients with socially dangerous pathologies




HIV, HIV epidemiology, socially dangerous pathologies, AIDS


The aim: to conduct a comparative analysis of HIV morbidity in Ukraine and in some countries of the European region over the years and to determine the characteristics of the epidemiological situation on this pathology.

Materials and methods. The object of the study was HIV incidence data presented on the website of the WHO European Health Portal (1990–2018) and in the Annual Report of the European Center for Disease Prevention and Control and the WHO Regional Office for Europe on HIV/AIDS Surveillance in Europe (2010–2019). Historical, analytical-comparative, systemic, graphic, logical, hypothetical-deductive, mathematical-statistical, epidemiological and other research methods were used.

Results. It is established that during 1990-2018 in the group of reference countries only for Ukraine and Belarus there was a significant fluctuation in the incidence rates presented in absolute data. In all countries except Romania, the number of HIV-infected in 2019 was higher than in 1990 (Ukraine, Belarus, Poland) and in 1993 (Germany). Analysis of the dynamics of the absolute number of HIV-infected persons by indicative years (1993, 1999, 2004, 2010, 2016, 2019) allows us to assert the different nature of changes in epidemiological data by group of reference countries. Only in Poland we saw a gradual increase in data for 1993-2019. In all other countries, there was a complex nature of changes in morbidity. According to the analysis of HIV incidence, presented in relative terms, it was found that they ranged in the largest range in Belarus, namely from 11.3 (2010) to 26.1 (2017). Belarus typically had the highest mean chain growth/decline rates of HIV incidence (1.09). In turn, the lowest value of these coefficients was observed in the EU as a whole (0.97). Comparison of average values of HIV incidence per 100 thousand population suggests that in Ukraine this figure was 1.85 times higher than in Belarus, 11.36 times higher than in Poland, 8.65 times higher than in Romania, 10.27 times higher than in Germany and 5.88 times more than in the EU group.

Conclusions. The presence of a complex and tense epidemiological situation with HIV infection in Ukraine in comparison with other countries of the reference group of countries suggests the need to implement comprehensive programs to counter the spread of this socially dangerous infection and introduce models for the rational use of limited health care resources and international funds

Author Biographies

Valeriia Yefremova, State Establishment «Luhansk State Medical University»


Department of Drug Technology, Organization and Economics of Pharmacy

Hanna Panfilova, National University of Pharmacy

Doctor of Pharmaceutical Sciences, Professor

Department of Organization and Economics of Pharmacy

Alla Lebedyn, National University of Pharmacy

PhD, Assistant

Department of Organization and Economics of Pharmacy

Gennadii Iurchenko, National University of Pharmacy

PhD, Associate Professor

Department of Organization and Economics of Pharmacy

Okseniuk Oksana, State Establishment «Luhansk State Medical University»

PhD, Assistant

Department of Drug Technology, Organization and Economics of Pharmacy

Chernukha Vitaly, National University of Pharmacy

PhD, Associate Professor

Department of Organization and Economics of Pharmacy

Tereshchenko Lyubov, National University of Pharmacy

PhD, Associate Professor

Department of Social Pharmacy

Chebernina Inna, State Establishment «Luhansk State Medical University»


Department of Pharmacology, Clinical Pharmacology and Clinical Pharmacy


  1. Corneli, A., Meagher, K., Henderson, G., Peay, H., Rennie, S. (2018). How Biomedical HIV Prevention Trials Incorporate Behavioral and Social Sciences Research: A Typology of Approaches. AIDS and Behavior, 23 (8), 2146–2154. doi:
  2. Ferris France, N., Macdonald, S. H.-F., Conroy, R. R., Chiroro, P., Ni Cheallaigh, D., Nyamucheta, M. et. al. (2019). “We are the change” – An innovative community-based response to address self-stigma: A pilot study focusing on people living with HIV in Zimbabwe. PLOS ONE, 14 (2), e0210152. doi:
  3. Spach, D. H. (2021). Epidemiology of HIV. National HIV Curriculum. Available at:
  4. Gokengin, D., Oprea, C., Begovac, J., Horban, A., Zeka, A. N., Sedlacek, D. et. al. (2018). HIV care in Central and Eastern Europe: How close are we to the target? International Journal of Infectious Diseases, 70, 121–130. doi:
  5. Murray, C. J. L., Ortblad, K. F., Guinovart, C., Lim, S. S., Wolock, T. M., Roberts, D. A. et. al. (2014). Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet, 384 (9947), 1005–1070. doi:
  6. Peters, L., Klein, M. B. (2015). Epidemiology of hepatitis C virus in HIV-infected patients. Current Opinion in HIV and AIDS, 10 (5), 297–302. doi:
  7. Klein, M. B., Rockstroh, J. K., Wittkop, L. (2016). Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Current Opinion in HIV and AIDS, 11 (5), 521–526. doi:
  8. Tedaldi, E. M., Minniti, N. L., Fischer, T. (2015). HIV-Associated Neurocognitive Disorders: The Relationship of HIV Infection with Physical and Social Comorbidities. BioMed Research International, 2015, 1–13. doi:
  9. Cohen, R. A., Seider, T. R., Navia, B. (2015). HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease? Alzheimer’s Research & Therapy, 7 (1). doi:
  10. Hoffmann, C., Welz, T., Sabranski, M., Kolb, M., Wolf, E., Stellbrink, H.-J., Wyen, C. (2016). Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Medicine, 18 (1), 56–63. doi:
  11. Alonso, A., Barnes, A. E., Guest, J. L., Shah, A., Shao, I. Y., Marconi, V. (2019). HIV Infection and Incidence of Cardiovascular Diseases: An Analysis of a Large Healthcare Database. Journal of the American Heart Association, 8 (14). doi:
  12. Ingle, S. M., May, M. T., Gill, M. J., Mugavero, M. J., Lewden, C. et. al. (2014). Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. Clinical Infectious Diseases, 59 (2), 287–297. doi:
  13. Kay, E. S., Batey, D. S., Mugavero, M. J. (2016). The HIV treatment cascade and care continuum: updates, goals, and recommendations for the future. AIDS Research and Therapy, 13 (1). doi:
  14. Luz, P. M., Veloso, V. G., Grinsztejn, B. (2019). The HIV epidemic in Latin America: accomplishments and challenges on treatment and prevention. Current Opinion in HIV and AIDS, 14 (5), 366–373. doi:
  15. Chammartin, F., Zürcher, K., Keiser, O., Weigel, R., Chu, K., Kiragga, A. N. et. al. (2018). Outcomes of Patients Lost to Follow-up in African Antiretroviral Therapy Programs: Individual Patient Data Meta-analysis. Clinical Infectious Diseases, 67 (11), 1643–1652. doi:
  16. Hernandez, I., Reina-Ortiz, M., Johnson, A., Rosas, C., Sharma, V., Teran, S. et. al. (2016). Risk Factors Associated With HIV Among Men Who Have Sex With Men (MSM) in Ecuador. American Journal of Men’s Health, 11 (5), 1331–1341. doi:
  17. Pantelic, M., Steinert, J. I., Park, J., Mellors, S., Murau, F. (2019). “Management of a spoiled identity”: systematic review of interventions to address self-stigma among people living with and affected by HIV. BMJ Global Health, 4 (2). doi:
  18. Gaist, P., Stirratt, M. J. (2017). The Roles of Behavioral and Social Science Research in the Fight Against HIV/AIDS: A Functional Framework. JAIDS Journal of Acquired Immune Deficiency Syndromes, 75 (4), 371–381. doi:
  19. Frank, T. D., Carter, A., Jahagirdar, D., Biehl, M. H., Douwes-Schultz, D., Larson, S. L. et. al. (2019). Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. The Lancet HIV, 6 (12), e831–e859. doi:
  20. Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J. et. al. (2018). Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA, 320 (4), 379–396. doi:
  21. HIV/AIDS surveillance in Europe 2020 (2019). WHO, 126. Available at:
  22. Ahmed, S., Autrey, J., Katz, I. T., Fox, M. P., Rosen, S., Onoya, D. et. al. (2018). Why do people living with HIV not initiate treatment? A systematic review of qualitative evidence from low- and middle-income countries. Social Science & Medicine, 213, 72–84. doi:
  23. Pellowski, J. A., Kalichman, S. C., Matthews, K. A., Adler, N. (2013). A pandemic of the poor: Social disadvantage and the U.S. HIV epidemic. American Psychologist, 68 (4), 197–209. doi:
  24. Saadat, V. M. (2016). HIV Risks, Testing, and Treatment in the Former Soviet Union: Challenges and Future Directions in Research and Methodology. Central Asian Journal of Global Health, 4 (2). doi:
  25. Amangaldiyeva, A., Davlidova, S., Baiserkin, B., Dzissyuk, N., DeHovitz, J., Ali, S. (2019). Implementation of antiretroviral therapy (ART) in former Soviet Union countries. AIDS Research and Therapy, 16 (1). doi:
  26. Rechel, B. (2010). HIV/AIDS in the Countries of the Former Soviet Union: Societal and Attitudinal Challenges. Central European Journal of Public Health, 18 (2), 110–115. doi:
  27. Piot, P., Caldwell, A., Lamptey, P., Nyrirenda, M., Mehra, S., Cahill, K., Aerts, A. (2016). Addressing the growing burden of non–communicable disease by leveraging lessons from infectious disease management. Journal of Global Health, 6 (1). doi:
  28. Frijters, E. M., Hermans, L. E., Wensing, A. M. J., Devillé, W. L. J. M., Tempelman, H. A., De Wit, J. B. F. (2020). Risk factors for loss to follow-up from antiretroviral therapy programmes in low-income and middle-income countries. AIDS, 34 (9), 1261–1288. doi:
  29. Dybul, M., Attoye, T., Baptiste, S., Cherutich, P., Dabis, F., Deeks, S. G. et. al. (2021). The case for an HIV cure and how to get there. The Lancet HIV, 8 (1), e51–e58. doi:
  30. Miners, A., Phillips, A., Kreif, N., Rodger, A., Speakman, A., Fisher, M., … Lampe, F. C. (2014). Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. The Lancet HIV, 1 (1), e32–e40. doi:
  31. Jacobson, J. M., Flexner, C. W. (2017). Universal antiretroviral regimens: thinking beyond one-pill-once-a-day. Current Opinion in HIV and AIDS, 12 (4), 343–350. doi:
  32. Chawla, A., Wang, C., Patton, C., Murray, M., Punekar, Y., de Ruiter, A., Steinhart, C. (2018). A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. Infectious Diseases and Therapy, 7 (2), 183–195. doi:
  33. Weld, E. D., Rana, M. S., Dallas, R. H., Camacho-Gonzalez, A. F., Ryscavage, P., Gaur, A. H. et. al. (2019). Interest of Youth Living With HIV in Long-Acting Antiretrovirals. JAIDS Journal of Acquired Immune Deficiency Syndromes, 80 (2), 190–197. doi:
  34. Number of new HIV diagnoses. European Health Information Gateway. Available at:
  35. Fang, J.-Q. (Ed.) (2017). Handbook of Medical Statistics. China: Sun Yat-Sen University, 850.
  36. Haas, A. D., Zaniewski, E., Anderegg, N., Ford, N., Fox, M. P. et. al. (2018). Retention and mortality on antiretroviral therapy in sub‐Saharan Africa: collaborative analyses of HIV treatment programmes. Journal of the International AIDS Society, 21 (2). doi:
  37. Hamers, R. L., Rinke de Wit, T. F., Holmes, C. B. (2018). HIV drug resistance in low-income and middle-income countries. The Lancet HIV, 5 (10), e588–e596. doi:
  38. Korzh, I., Romanko, T., Volkova, A., Tereshсhenko, L. (2021). The structural analysis of government expenditures on the purchase of antituberculous drugs. ScienceRise: Pharmaceutical Science, 2 (30), 17–25. doi:
  39. Katz, I. T., Maughan-Brown, B. (2017). Improved life expectancy of people living with HIV: who is left behind? The Lancet HIV, 4 (8), e324–e326. doi:
  40. Marcus, J. L., Chao, C. R., Leyden, W. A., Xu, L., Quesenberry, C. P., Klein, D. B. et. al. (2016). Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. JAIDS Journal of Acquired Immune Deficiency Syndromes, 73 (1), 39–46. doi:
  41. Mateo-Urdiales, A., Johnson, S., Smith, R., Nachega, J. B., Eshun-Wilson, I. (2019). Rapid initiation of antiretroviral therapy for people living with HIV. Cochrane Database of Systematic Reviews, 6. doi:
  42. Kotvitska, A., Volkova, A., Korzh, I., Surikova, I. (2021). Comparative analysis of indicators that determine the effectiveness of the implementation of socio-economic determinants of health in Europe and Ukraine. ScienceRise: Pharmaceutical Science, 3 (31), 34–41. doi:




How to Cite

Yefremova, V., Panfilova, H., Lebedyn, A., Iurchenko, G., Oksana, O., Vitaly, C., Lyubov, T., & Inna, C. (2022). The results of a comparative analysis of the population of the population of Ukraine and countries of the European region for HIV as a rationale for improving the pharmaceutical provision of patients with socially dangerous pathologies. ScienceRise: Pharmaceutical Science, (1(35), 4–13.



Pharmaceutical Science

Most read articles by the same author(s)